Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Post by FredTheVoiceon Mar 18, 2018 9:37am
138 Views
Post# 27735355

the best option

the best option
JFM1330 wrote: "
So with that much potential, I really don't want to see a financing at C$10 per share just to get a fast listing on the NASDAQ. It would be giving away a part of what we own for no good reason. Anyway. This stock won't stay at at C$9.70 for very long. We all know the market is sometime inefficient, but as Garp1 wrote, some momentum brokers will wake up to this story and I think Tanguay and Dubuc will make sure that it happens. There were reasons to be impatient and frustrated in the last two years, but not now. We got what we were all hoping for: approval. We got the thoughest part. Now we just need to give Thera time to execute. I have a high degree of confodence that they will deliver and that the stock price will follow. It's just a matter of time now ans a matter of a little more patience".

Its the best post I read. I posted only the conclusion from a great post from JFM1330. Confidence and patience. Nasdaq wont give us that. Im not saying that eventually it wont be a good option. But not in a short term I think. Not even a bought deal.
In one of my scenarios I posted here, one touched (I was lucky) it right on the nose. That the share price after approval would rise 30%.
So im giving it a try one more time. My guess, is that selling even ONE SHARE in the next six months to one year is a very bad idea. I noted once before that this stock is very close to rise as it did in 2000 and 2007. Take a look by yourself at the charts. More than a double in a short period of time. A stock like TH visits that experience once each ten years if it does.........and my bet, is that we are very near of that reality. One wrote yesterday that people often leave the boat to early ......again, nervousseness and incapacity to MANAGE EUPHORIA. Only a few have the skill and experience to face those situation.
Dont miss the ride.
FTV.
Bullboard Posts